Lupin Ltd (Lupin) undertakes the manufacture and marketing of generic and branded pharmaceutical products, and active pharmaceutical ingredients (APIs). The company focuses on therapeutic areas such as generics, biosimilars, specialty, over-the-counter, active pharmaceutical ingredients, global institutional business, tech-driven offerings. It is one of the leading and fasting growing companies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company focuses its research and development programs on the discovery of new biosimilars in the areas of pain, inflammation, metabolic and endocrine diseases, auto immune diseases, central nervous system disorders, oncology and infectious diseases. These advanced drug delivery platforms enable the company to produce value added generic and branded pharmaceuticals. The company has a strong portfolio of products for including 463 ANDAs and four NDAs which have been approved by the US FDA. The company has seven research facilities in India: Pune & Aurangabad, U.S; New Jersey & Florida, LATAM; Mexico & Brazil Europe; Netherlands. The company has 911 active patents. It has 1,400 employees for R&D activities. In FY2023 Lupin’s expenditure on R&D amounted to INR12,800.1 million, which as a percentage stood at 7.69%.